NCT01734993View on ClinicalTrials.gov

A Long-Term Extension Study of WA22762 to Evaluate Safety and Efficacy of Subcutaneous Tocilizumab in Participants With Moderate to Severe Rheumatoid Arthritis (RA).

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

September 30, 2015

Study Completion Date

September 30, 2015

Conditions

Rheumatoid Arthritis

Interventions

DRUG

Tocilizumab

Participants will receive TCZ 162 milligrams (mg) SC injection once a week.

Trial Locations (6)

31059

Toulouse

33076

Bordeaux

34295

Montpellier

44035

Nantes

67098

Strasbourg

75679

Paris

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY

NCT01734993 - A Long-Term Extension Study of WA22762 to Evaluate Safety and Efficacy of Subcutaneous Tocilizumab in Participants With Moderate to Severe Rheumatoid Arthritis (RA). | Biotech Hunter | Biotech Hunter